By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Esperion Therapeutics, Inc. 

3621 S. State Street
695 KMS Place
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-332-0506 Fax: 734-332-0516

Esperion Therapeutics, Inc., is a biopharmaceutical company dedicated to the discovery, development and commercialization of a novel class of therapies to treat cardiovascular and metabolic diseases, including atherosclerosis, as they relate to high density lipoprotein cholesterol, "HDL-C", also known as the "good" cholesterol.

The technology platform for Esperion is based upon the Reverse Lipid Transport (RLT) pathway. The RLT pathway is responsible for removing excess cholesterol and other lipids from arterial walls and other tissues for transport to the liver and elimination from the body. The Company's product candidates work by stimulating the RLT pathway through the enhancement of key HDL properties, which may result in improved vascular structure and function. Esperion is focusing its efforts on developing both acute and chronic therapies for cardiovascular and metabolic diseases.

Esperion was founded in 1998 by, among others, members of the Warner-Lambert/Parke-Davis (now Pfizer) team that discovered and developed atorvastatin, the highly successful multibillion-dollar drug. Since that time, an additional group of exceptional scientists and specialists has joined the Company. Many of these individuals have been instrumental in the discovery, development and commercialization of several of the pharmaceutical industry's most successful therapies. It is this combined team that makes Esperion a leading enterprise in HDL drug discovery and research.

Key Management:

  • Roger Newton, Ph.D.
    President and CEO
  • Timothy Mayleben
    Chief Operating Officer and CFO

    Last Updated: 01-18-05

    Key Statistics

    Ownership: Public

    Web Site: Esperion
    Symbol: ESPR

  • Industry

    Company News
    Esperion (ESPR) Hits A New High After Positive Feedback For Its Heart Drug From The FDA 3/20/2017 7:42:03 AM
    Esperion (ESPR) Announces Initiation Of Phase II Triplet Oral Therapy Study Of Bempedoic Acid/Ezetimibe/Atorvastatin 3/7/2017 8:13:03 AM
    Esperion (ESPR) Announces Oral Presentation On Genetic Validation Of ATP Citrate Lyase Inhibition At American College of Cardiology 66th Annual Scientific Session 3/6/2017 9:54:52 AM
    Esperion (ESPR) Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter And Full Year 2016 Financial Results 2/22/2017 7:49:00 AM
    Esperion (ESPR) To Participate In Fireside Chat At RBC Capital Markets Global Healthcare Conference 2/16/2017 9:13:33 AM
    Esperion (ESPR) Release: Pharma Completes Enrollment Of Pivotal Phase 3 Long-Term Safety And Tolerability Study Of Bempedoic Acid In Patients With Hypercholesterolemia 1/25/2017 11:33:40 AM
    Esperion (ESPR) Announces Initiation Of Global Cardiovascular Outcomes Trial For Bempedoic Acid 1/9/2017 11:27:53 AM
    Esperion (ESPR) Announces Initiation Of Three Pivotal Phase 3 Studies For Bempedoic Acid 1/9/2017 9:41:10 AM
    Esperion (ESPR) To Present At The 35th Annual J.P. Morgan Healthcare Conference 1/5/2017 9:14:03 AM
    Esperion (ESPR) Announces Publication Of Definitive Paper On Bempedoic Acid Mechanism Of Action In Nature Communications 11/29/2016 10:16:15 AM